Stocks Overview

LAST PRICE
2.7500
TODAY'S CHANGE (%)
Trending Up0.1400 (5.3640%)

Bid / Lots
2.7500/ 96
Ask / Lots
2.7700/ 2
Open / Previous Close
2.6000 / 2.6100
Day Range
Low 2.4800
High 2.7700
52 Week Range
Low 2.0050
High 8.7200
Volume
1,046,971
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 2.61
Time	Volume	STRO
09:32 ET	9656	2.55
09:33 ET	4466	2.56
09:35 ET	4607	2.57
09:37 ET	2067	2.59
09:39 ET	5896	2.5711
09:42 ET	15393	2.555
09:44 ET	1900	2.53
09:46 ET	2903	2.54
09:48 ET	3099	2.53
09:50 ET	1100	2.53
09:51 ET	1450	2.52
09:53 ET	3967	2.51
09:55 ET	1100	2.52
09:57 ET	4900	2.525
10:00 ET	100	2.526
10:02 ET	700	2.53
10:04 ET	2640	2.5475
10:06 ET	3400	2.545
10:08 ET	800	2.525
10:09 ET	858	2.52
10:11 ET	1100	2.52
10:13 ET	6710	2.51
10:15 ET	21307	2.51
10:18 ET	1500	2.52
10:20 ET	550	2.52
10:22 ET	400	2.51
10:24 ET	2917	2.54
10:26 ET	1581	2.5475
10:27 ET	4547	2.5413
10:31 ET	7351	2.545
10:33 ET	1370	2.555
10:36 ET	6756	2.545
10:38 ET	500	2.55
10:40 ET	3854	2.55
10:42 ET	600	2.5575
10:44 ET	5600	2.55
10:45 ET	3200	2.55
10:47 ET	200	2.5575
10:49 ET	200	2.55
10:51 ET	600	2.55
10:54 ET	701	2.545
10:56 ET	300	2.54
10:58 ET	100	2.54
11:00 ET	1600	2.55
11:02 ET	3617	2.545
11:03 ET	1050	2.53
11:05 ET	200	2.53
11:07 ET	1000	2.55
11:12 ET	6189	2.555
11:14 ET	100	2.55
11:16 ET	9225	2.56
11:18 ET	2529	2.565
11:20 ET	100	2.56
11:21 ET	300	2.55
11:23 ET	200	2.555
11:25 ET	500	2.555
11:27 ET	1100	2.5575
11:30 ET	5759	2.56
11:32 ET	3507	2.565
11:34 ET	300	2.565
11:36 ET	2703	2.57
11:38 ET	600	2.57
11:39 ET	400	2.574
11:41 ET	9980	2.59
11:43 ET	6881	2.61
11:45 ET	900	2.605
11:48 ET	7340	2.595
11:50 ET	100	2.595
11:52 ET	1222	2.59
11:54 ET	2900	2.6
11:56 ET	2467	2.6
11:57 ET	1900	2.6
11:59 ET	3569	2.6
12:01 ET	100	2.6
12:03 ET	1851	2.6
12:06 ET	200	2.6
12:08 ET	2155	2.6
12:10 ET	1246	2.61
12:12 ET	200	2.61
12:14 ET	300	2.61
12:15 ET	2000	2.61
12:17 ET	100	2.61
12:19 ET	1638	2.605
12:21 ET	200	2.605
12:24 ET	1900	2.61
12:26 ET	494	2.61
12:28 ET	100	2.61
12:30 ET	3300	2.615
12:32 ET	1525	2.61
12:33 ET	3106	2.61
12:35 ET	1500	2.62
12:37 ET	300	2.6275
12:39 ET	4301	2.62
12:42 ET	307	2.6275
12:44 ET	200	2.6275
12:46 ET	1600	2.62
12:48 ET	1286	2.635
12:50 ET	1700	2.63
12:51 ET	312	2.6375
12:53 ET	1017	2.62
12:55 ET	957	2.62
12:57 ET	6655	2.625
01:00 ET	1988	2.615
01:02 ET	302	2.61
01:04 ET	300	2.615
01:06 ET	3012	2.61
01:08 ET	3000	2.61
01:09 ET	220	2.61
01:11 ET	762	2.61
01:13 ET	1414	2.605
01:15 ET	1300	2.605
01:18 ET	500	2.6
01:20 ET	900	2.6
01:22 ET	3209	2.61
01:24 ET	1700	2.61
01:26 ET	2022	2.6
01:27 ET	880	2.595
01:29 ET	600	2.5975
01:31 ET	5698	2.6075
01:33 ET	2471	2.61
01:36 ET	2341	2.6175
01:38 ET	717	2.62
01:40 ET	3651	2.62
01:42 ET	2010	2.65
01:44 ET	8037	2.63
01:45 ET	400	2.63
01:47 ET	1302	2.63
01:49 ET	5300	2.64
01:51 ET	4635	2.645
01:54 ET	2637	2.64
01:56 ET	3436	2.64
01:58 ET	4866	2.65
02:00 ET	3443	2.65
02:02 ET	4938	2.65
02:03 ET	3100	2.65
02:05 ET	3213	2.66
02:07 ET	7870	2.67
02:09 ET	5625	2.7
02:12 ET	700	2.7
02:14 ET	700	2.695
02:16 ET	1642	2.7075
02:18 ET	300	2.7075
02:20 ET	2681	2.73
02:21 ET	2200	2.73
02:23 ET	3897	2.73
02:25 ET	2074	2.73
02:27 ET	4352	2.71
02:30 ET	2159	2.7
02:32 ET	10400	2.7
02:34 ET	101469	2.7
02:36 ET	22964	2.7
02:38 ET	500	2.7
02:39 ET	1006	2.705
02:41 ET	2445	2.7
02:43 ET	2760	2.7
02:45 ET	7492	2.71
02:48 ET	12308	2.74
02:50 ET	16797	2.735
02:52 ET	8162	2.72
02:54 ET	8248	2.72
02:56 ET	7772	2.7394
02:57 ET	500	2.7375
02:59 ET	3328	2.74
03:01 ET	700	2.735
03:03 ET	700	2.73
03:06 ET	700	2.73
03:08 ET	13628	2.735
03:10 ET	5663	2.735
03:12 ET	1100	2.735
03:14 ET	2963	2.735
03:15 ET	3059	2.73
03:17 ET	500	2.74
03:19 ET	2662	2.72
03:21 ET	3967	2.735
03:24 ET	2600	2.735
03:26 ET	5636	2.73
03:28 ET	1575	2.735
03:30 ET	15808	2.73
03:32 ET	3839	2.735
03:33 ET	1565	2.735
03:35 ET	4942	2.735
03:37 ET	1600	2.735
03:39 ET	5416	2.735
03:42 ET	3095	2.735
03:44 ET	48052	2.735
03:46 ET	3745	2.725
03:48 ET	23294	2.735
03:50 ET	3919	2.74
03:51 ET	2031	2.735
03:53 ET	19161	2.745
03:55 ET	11192	2.76
03:57 ET	24658	2.77
04:00 ET	11339	2.75

Data delayed at least 15 minutes.

Nov 27, 2023
- DJ Vaxcyte Exercises Right to Manufacture Sutro Biopharma's Cell-Free Extract, from 4:18PM ET on Monday Nov 27, 2023 by Dow Jones
  4:18PM ET on Monday Nov 27, 2023 by Dow Jones
- Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates, from 4:00PM ET on Monday Nov 27, 2023 by Dow Jones
  4:00PM ET on Monday Nov 27, 2023 by Dow Jones
Nov 21, 2023
- DJ Sutro Biopharma Names Jane Chung as Next Operating Chief, from 4:47PM ET on Tuesday Nov 21, 2023 by Dow Jones
  4:47PM ET on Tuesday Nov 21, 2023 by Dow Jones
- Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer, from 4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones
  4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones
- Press Release: Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer, from 4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones
  4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesSTRO Sutro Biopharma Inc	167.6M	-0.9x	---
United StatesALIM Alimera Sciences Inc	176.1M	-1.3x	---
United StatesCDXC Chromadex Corp	105.9M	-16.3x	---
United StatesIPHA Innate Pharma SA	198.0M	-2.8x	---
United StatesENTA Enanta Pharmaceuticals Inc	205.5M	-1.5x	---
United StatesPSNL Personalis Inc	72.1M	-0.6x	---
As of 2023-12-02

Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It provides two wholly owned ADCs in the clinic, namely luveltamab tazevibulin (STRO-002 or luvelta) and STRO-001. STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. STRO-001 is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma (NHL). Its preclinical product candidate, STRO-003, is a single homogeneous ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), developed for the treatment of solid tumors.

Contact Information

Headquarters: 111 Oyster Point Blvd.SOUTH SAN FRANCISCO, CA, United States 94080
Phone: 650-392-8412
Fax: 302-655-5049

Executives

Independent Chairman of the Board: Connie Matsui
President, Chief Operating Officer: Jane Chung
Chief Executive Officer, Director: William Newell
Chief Financial Officer: Edward Albini
Chief People and Communications Officer: Linda Fitzpatrick

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

Fundamentals Table
Market Cap	$167.6M
Revenue (TTM)	$48.6M
Shares Outstanding	61.0M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.83
EPS	$-2.91
Book Value	$3.77
P/E Ratio	-0.9x
Price/Sales (TTM)	3.4
Price/Cash Flow (TTM)	---
Operating Margin	-373.45%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Sutro Biopharma Inc
NASDAQ:STROUnited States

Search Criteria

Charts

Recent News

Nov 27, 2023

DJ Vaxcyte Exercises Right to Manufacture Sutro Biopharma's Cell-Free Extract, from 4:18PM ET on Monday Nov 27, 2023 by Dow Jones

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates, from 4:00PM ET on Monday Nov 27, 2023 by Dow Jones

Nov 21, 2023

DJ Sutro Biopharma Names Jane Chung as Next Operating Chief, from 4:47PM ET on Tuesday Nov 21, 2023 by Dow Jones

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer, from 4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones

Press Release: Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer, from 4:05PM ET on Tuesday Nov 21, 2023 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar